3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Active not recruiting
2
Sponsor Class
NIH
2
INDUSTRY
2
OTHER
1
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Other hematologic neoplasm
1
Conditions
Colorectal Neoplasms
108
Stomach Neoplasms
68
Pancreatic Neoplasms
33
Neoplasms
24
Lymphoma, Large B-Cell, Diffuse
22
Carcinoma, Non-Small-Cell Lung
21
Neoplasm Metastasis
18
Rectal Neoplasms
17
Colonic Neoplasms
17
Esophageal Neoplasms
16
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Adenocarcinoma
13
Carcinoma, Hepatocellular
12
Ovarian Neoplasms
10
Biliary Tract Neoplasms
9
Adenocarcinoma Of Esophagus
9
Esophageal Squamous Cell Carcinoma
8
Cholangiocarcinoma
8
Gastrointestinal Neoplasms
7
Lymphoma, Non-Hodgkin
6
Endometrial Neoplasms
6
Gallbladder Neoplasms
5
Advanced Solid Tumors
5
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Recurrence
4
Carcinoma, Pancreatic Ductal
4
Breast Neoplasms
4
Advanced Solid Tumor
4
Solid Tumors
3
Interventions
Rituximab
90
Cyclophosphamide
30
Lenalidomide
28
Bendamustine Hydrochloride
24
Prednisone
20
Vincristine
19
obinutuzumab
17
Doxorubicin
16
fludarabine
14
ibrutinib
13
tazemetostat
9
idelalisib
9
Deoxycholic Acid
9
parsaclisib
8
Prednisolone
8
zanubrutinib
7
venetoclax
7
tofacitinib
7
tisagenlecleucel
5
pembrolizumab
5
ofatumumab
5
ibritumomab tiuxetan
5
duvelisib
5
Gemcitabine
5
Bortezomib
5
durvalumab
4
aflibercept
4
R-CHOP protocol
4
Methylprednisolone
4
Methotrexate
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, Follicular
×
Oxaliplatin
×
Clear all
NCT04542824
2026-06-02
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2
Active not recruiting
78 enrolled
NCT04663347
2026-06-02
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2
Active not recruiting
543 enrolled